Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)
- PMID: 22827572
- DOI: 10.1021/jm300713s
Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)
Abstract
Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors. Through screening and lead optimization using the human PERK crystal structure, we discovered compound 38 (GSK2606414), an orally available, potent, and selective PERK inhibitor. Compound 38 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice.
Similar articles
-
Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.Bioorg Med Chem. 2012 Jan 1;20(1):125-36. doi: 10.1016/j.bmc.2011.11.023. Epub 2011 Nov 20. Bioorg Med Chem. 2012. PMID: 22169601
-
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.Bioorg Med Chem. 2014 Sep 1;22(17):4998-5012. doi: 10.1016/j.bmc.2014.06.025. Epub 2014 Jun 21. Bioorg Med Chem. 2014. PMID: 25009002
-
Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.J Med Chem. 2011 Dec 8;54(23):8030-50. doi: 10.1021/jm2008634. Epub 2011 Nov 4. J Med Chem. 2011. PMID: 22003817
-
Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. doi: 10.1080/13543776.2017.1238072. Epub 2016 Sep 23. Expert Opin Ther Pat. 2017. PMID: 27646439 Review.
-
Tumor progression and the different faces of the PERK kinase.Oncogene. 2016 Mar 10;35(10):1207-15. doi: 10.1038/onc.2015.178. Epub 2015 Jun 1. Oncogene. 2016. PMID: 26028033 Free PMC article. Review.
Cited by
-
The integrated stress response.EMBO Rep. 2016 Oct;17(10):1374-1395. doi: 10.15252/embr.201642195. Epub 2016 Sep 14. EMBO Rep. 2016. PMID: 27629041 Free PMC article. Review.
-
Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases.Curr Opin Chem Biol. 2013 Jun;17(3):346-52. doi: 10.1016/j.cbpa.2013.04.009. Epub 2013 May 4. Curr Opin Chem Biol. 2013. PMID: 23647985 Free PMC article. Review.
-
Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.Int J Mol Sci. 2020 Aug 31;21(17):6314. doi: 10.3390/ijms21176314. Int J Mol Sci. 2020. PMID: 32878237 Free PMC article.
-
Small molecule strategies to harness the unfolded protein response: where do we go from here?J Biol Chem. 2020 Nov 13;295(46):15692-15711. doi: 10.1074/jbc.REV120.010218. Epub 2020 Sep 4. J Biol Chem. 2020. PMID: 32887796 Free PMC article. Review.
-
PERK-mediated induction of microRNA-483 disrupts cellular ATP homeostasis during the unfolded protein response.J Biol Chem. 2020 Jan 3;295(1):237-249. doi: 10.1074/jbc.RA119.008336. Epub 2019 Dec 2. J Biol Chem. 2020. PMID: 31792031 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases